Vyriad Reshapes Executive Leadership Team as It Prepares for Next Phase of Growth in In Vivo CAR T and Viral Delivery Therapies
Vyriad, Inc., a clinical-stage biotechnology company focused on developing targeted genetic therapies for cancer and other serious diseases, has announced a significant reorganization of its executive leadership team as it positions itself for the next stage of clinical and corporate growth. The company said Luke Russell, Ph.D., MBA, has been promoted to president and will also join Vyriad’s board of directors, while Stephen Russell, M.D., Ph.D., the company’s co-founder and current president, will transition into the roles of chief scientific officer (CSO) and executive chairman.
The leadership changes come at a time when Vyriad is seeking to build momentum around its oncology pipeline and its efforts to develop in vivo CAR T therapies and other cell-based treatments using its proprietary viral delivery technologies. The company framed the move as a strategic realignment designed to strengthen both operational execution and scientific leadership as it advances a growing portfolio of programs toward the clinic.
According to Vyriad, the restructuring reflects the increasing scale and complexity of its business, particularly as it pursues new opportunities in cell therapy, expands its partnerships, and prepares for clinical milestones expected later this year.
Leadership transition reflects a company entering a new stage
Vyriad’s announcement underscores that the company sees itself at an inflection point in its development. In recent months, the biotechnology company has highlighted progress in both its technology platform and financing strategy, and the new leadership structure appears intended to support that acceleration.
Luke Russell, who is moving into the president role, described the company as entering one of the most ambitious chapters in its history. He pointed to rapid advances in oncology and in vivo CAR T therapy as areas where Vyriad believes it has an opportunity to make a meaningful impact, particularly through its viral delivery platform.
Russell said the company is looking to build on its recent presence at the American Society of Gene & Cell Therapy (ASGCT) meeting, where it showcased data intended to demonstrate the potential of its first-in-class viral delivery approach. He suggested that the technology could offer a disruptive new way to deliver cell therapies in vivo, potentially broadening access and simplifying treatment approaches that have traditionally been complex and resource-intensive.
As president, Luke Russell will now be tasked with overseeing the company’s broader operational and business execution at a time when Vyriad is balancing scientific innovation with the practical demands of scaling a clinical-stage biotechnology company. His appointment to the board also signals a desire to integrate day-to-day operational leadership more closely with strategic oversight at the board level.
Luke Russell steps into the presidency after expanding business leadership role
Vyriad noted that Luke Russell has taken on increasingly senior responsibilities during his time at the company, making his promotion a natural progression in its leadership evolution. Prior to being named president, he served as executive vice president, where he played a major role in business development, strategic partnerships, and broader corporate leadership.
The company credited him with helping secure and manage Vyriad’s ongoing collaborations with Regeneron Pharmaceuticals and Novartis, two partnerships that are likely to be viewed as important validations of the company’s technology and long-term potential. Those relationships have helped position Vyriad within a competitive landscape where partnerships with larger pharmaceutical companies can provide not only capital and external validation, but also access to development expertise and strategic resources.
Luke Russell’s background in business development appears to be one of the main reasons the company believes he is well suited for the presidency. As Vyriad moves closer to the clinic with its lead in vivo CAR T program and other platform initiatives, leadership with experience in both strategic deal-making and organizational management could prove especially valuable.
The company also appears to be betting that Russell can help translate platform promise into operational momentum. Moving from executive vice president to president places him at the center of the company’s next growth phase, with responsibility for guiding corporate strategy, partnerships, clinical preparation, and execution across a rapidly evolving therapeutic portfolio.
Stephen Russell shifts focus toward scientific leadership and board oversight
As part of the transition, Stephen Russell, Vyriad’s co-founder and current president, will step away from the top operational role and take on a more science-centered and strategic leadership position. In his new role as chief scientific officer, he will focus on advancing the company’s next-generation viral delivery and cell therapy innovations, which remain central to Vyriad’s long-term vision.
Stephen Russell has been instrumental in shaping Vyriad’s scientific direction since the company’s founding, and the move appears designed to allow him to concentrate more fully on the research and translational work underpinning the company’s pipeline. As the company expands its clinical-stage portfolio and seeks to bring increasingly sophisticated in vivo cell therapy approaches into human studies, maintaining strong scientific leadership will be essential.
Vyriad said Russell will continue to play a foundational role in guiding the scientific strategy behind its platform, particularly in areas involving viral delivery and in vivo engineering of cell therapies. These technologies are intended to address some of the limitations associated with traditional ex vivo CAR T approaches, including manufacturing complexity, cost, and access constraints.
In addition to becoming CSO, Stephen Russell will also assume the role of executive chairman, giving him a formal leadership position on the board of directors. In that capacity, he will work closely with Luke Russell to ensure that Vyriad’s corporate strategy and scientific priorities remain aligned as the company scales. The arrangement suggests an effort to separate operational leadership from scientific oversight without losing continuity between the company’s founding vision and its current growth strategy.
Stephen Russell said the company’s operations and scientific pipeline have grown to the point where they now require dedicated executive focus in each area. Having worked closely with Luke Russell in building Vyriad’s foundation, he said he believes the incoming president has the operational leadership and expertise needed to guide the company through its next phase.
Board backs new structure as Vyriad scales business and pipeline
The leadership transition has also been endorsed by Vyriad’s board, which framed the move as a way to strengthen the balance between scientific stewardship and business execution. Ed Kania, the board’s lead director, said Stephen Russell’s contributions have been instrumental to the company’s development and emphasized that his continued role as CSO will remain critical to Vyriad’s future success.
Kania also expressed confidence in Luke Russell’s expanded leadership role, saying the board believes the revised executive structure positions Vyriad well for future growth. The company appears to be presenting the changes not as a departure from its existing strategy, but rather as an evolution intended to support the next stage of execution.
That distinction is important for a clinical-stage biotechnology company like Vyriad, where leadership continuity can matter significantly to investors, partners, and employees. By keeping Stephen Russell deeply involved in both scientific leadership and board oversight while elevating Luke Russell into the president’s role, Vyriad is signaling that it wants to preserve the company’s founding scientific vision while also sharpening its focus on operational scaling and clinical advancement.
Recent milestones highlight Vyriad’s broader ambitions in in vivo cell therapy
The executive restructuring comes amid a series of milestones that Vyriad says reflect growing momentum across its business and development programs. In recent months, the company has advanced its efforts to develop more accessible, or “democratized,” in vivo CAR T and other cell therapies by pursuing technologies designed to simplify delivery and potentially broaden the use of cell-based treatments beyond specialized manufacturing settings.
Among those milestones is the launch of G-Link, a modular adaptor protein platform intended to streamline the delivery of in vivo CAR T therapies. Vyriad has described G-Link as a technology that could help simplify the process of targeting and activating in vivo CAR T systems, potentially enhancing the flexibility and usability of its therapeutic platform.
The company has also strengthened its financial position, recently completing a total $85 million Series B financing. That capital raise provides additional support for Vyriad’s clinical and platform ambitions and suggests investor confidence in the company’s strategy. For a biotech company working in a complex and capital-intensive area such as in vivo cell therapy, financing is a critical component of progress, particularly as programs approach clinical testing.
Vyriad said it plans to initiate clinical trials later this year for its lead in vivo CAR T program as well as for G-Link translation efforts. Those upcoming studies are expected to be major milestones for the company, potentially offering the first clinical evidence of how its platform performs in patients and whether its viral delivery approach can open new possibilities in cell therapy development.
Positioning for a high-stakes phase of execution
Taken together, the leadership changes and recent pipeline milestones suggest Vyriad is entering a period of heightened activity and strategic importance. The company is attempting to advance a differentiated approach in one of the most closely watched areas of biotechnology—cell therapy—while also navigating the practical realities of becoming a more mature clinical-stage enterprise.
By elevating Luke Russell to president and giving Stephen Russell a more focused role in scientific leadership and board oversight, Vyriad appears to be aligning its executive structure with the dual demands of innovation and execution. The company will need both as it moves toward clinical trials, deepens its partnerships, and works to demonstrate that its in vivo viral delivery platform can produce meaningful therapeutic results.
For now, the leadership transition marks an important organizational milestone for Vyriad. It reflects a company trying to prepare itself not only for its next set of clinical catalysts, but also for the broader challenge of turning promising science into sustainable development and, ultimately, patient impact in oncology and beyond.
About Vyriad
Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells. Vyriad’s programs include oncolytic virotherapy, in vivo gene therapy, and gene editing applications, with ongoing Phase 1–2 trials in multiple cancer indications. Vyriad is a privately held company based in Rochester, Minnesota.
